Due to this important trial, the ESMO guidelines have already implemented T‐DXd as a treatment option in case of metastatic Her2-positive breast cancer progressing after first-line treatment with a taxane plus trastuzumab/pertuzumab [3]. Here, ERBB2 is linked to breast carcinoma.